GET DAILY SIGNALSRadNet (RDNT) Analyst Targets Suggest a Modest +13% to +14% Path to $90
Key Takeaways
- The $90 central target is the arithmetic mean of six verified analyst price targets, rounded from roughly $89.83, spanning a range of $79 to $96.
- With the stock changing hands near $79–$80, reaching $90 would require a gain of roughly 13% to 14% — a modest but meaningful move.
- Bullish support rests on RadNet's national outpatient imaging footprint, strong demand tailwinds, and its AI-enabled Digital Health and DeepHealth initiatives.
- The biggest risks include reimbursement and payer pressure, questions raised about the AI segment's economics, and a valuation that discounts meaningful future execution.
- Views differ on how much credit to give the AI story: targets cluster from the low-$80s to the mid-$90s, reflecting genuine analyst disagreement rather than a uniform call.
- RadNet carries no dividend and is not yet profitable on a trailing basis, so the investment case hinges on forward earnings growth.
- You can find more detail on Major News, Today's Price Move, the Forecast, and Earnings on dedicated pages.
- For automated market scanning and signal ideas, explore Trending AI Robots.
Breaking Down the Analyst Consensus
RadNet, Inc. (RDNT) operates as a Los Angeles-based provider of outpatient diagnostic imaging services, including MRI, CT, PET, mammography, and ultrasound, through its Imaging Centers and Digital Health segments. To arrive at a central target, I reviewed six current analyst price targets: Barclays (Andrew Mok) at $79, B. Riley Securities (Yuan Zhi) at $83, KeyBanc (Matthew Gillmor) at $92, Truist (David Macdonald) at $94, Raymond James (John Ransom) at $95, and Jefferies at $96. The arithmetic mean comes in at approximately $89.83, which rounds cleanly to a $90 central target.
The range from $79 to $96 remains relatively tight for a growth-oriented name, yet it highlights meaningful differences in outlook. The more cautious Barclays target implies limited near-term credit for the AI opportunity, while the higher targets from Truist, Raymond James, and Jefferies give more weight to scale, demand trends, and digital offerings. Recent revisions have leaned constructive overall, with Truist raising its target after second-quarter results and Raymond James holding steady despite short-seller commentary on the AI segment.
Current Positioning and the Road to $90
In early November 2026, RDNT traded near $79–$80, below its 52-week high of about $85.84 yet well above the 52-week low near $50.82. Closing the gap to $90 from current levels would require roughly 13% to 14% upside. That represents a measured advance for a healthcare growth story, but it still depends on the market recognizing ongoing revenue expansion and margin improvement rather than simply maintaining the status quo.
Trailing revenue stands at approximately $2.38 billion, reflecting about 21% year-over-year growth. However, the company posted a net loss on a trailing basis, and the forward P/E remains in triple digits. This setup positions the stock as a bet on volume growth and AI monetization rather than a value play. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Management highlighted interconnected capabilities at its investor day, which supported target increases through late 2026.
Factors That Could Support Further Gains
- Scale and demand: RadNet runs one of the largest U.S. outpatient imaging networks and stands to benefit from secular growth in diagnostic imaging plus an aging population.
- AI optionality: The Digital Health segment, encompassing DeepHealth OS and AI tools for breast, lung, and prostate screening, provides an additional growth vector beyond core imaging volumes.
- Positive analyst revisions: Several firms lifted price targets in 2026 following strong results and an upbeat investor day.
- Revenue momentum: Double-digit top-line growth underscores robust demand even as profitability has yet to materialize.
Key Risks to Monitor
- Reimbursement and payer pressure: As a provider, RadNet remains exposed to reimbursement rate changes and payer consolidation that can pressure imaging margins.
- AI segment uncertainty: Digital Health still represents a modest revenue share, and short-seller scrutiny has focused on its growth trajectory and economics.
- Valuation: Negative trailing earnings combined with a premium forward multiple leave room for compression if growth disappoints.
- Profitability execution: The core test remains converting revenue growth into sustainable EPS improvement.
Technical Levels Worth Watching
The stock has maintained a broad uptrend, holding above both its 50-day and 200-day moving averages. The 52-week high near $85.84 sits between current prices and the $90 target and could serve as initial resistance. On the downside, the $72–$73 zone, where shares consolidated in early November, provides nearby support, with the 50-day average in the low-$70s as a secondary reference. A sustained push toward $90 would likely need to clear the prior high first.
Time Horizon and Items to Track
Analyst targets typically reflect a 12-month horizon, though the underlying calls here were issued at varying points across 2026. Investors should focus on quarterly earnings and guidance, especially margin trends and updates on Digital Health and AI revenue, along with reimbursement developments, further target revisions, and any responses to short-seller commentary. Signs of decelerating revenue growth or shortfalls in AI economics would carry the most weight for the path to $90.
Exploring AI Daily Buy/Sell Signals
In my own research process, I find it helpful to layer in quantitative signals alongside fundamental analysis. Tickeron's AI Daily Buy/Sell Signals apply artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. This approach can surface timely opportunities and help track evolving trends more efficiently than manual review alone.
Final Assessment
The $90 central target for RadNet represents the rounded mean of six analyst targets ranging from $79 to $96 and implies a modest 13% to 14% advance from recent levels near $79–$80. The bull case centers on a leading outpatient imaging network, double-digit revenue growth, and an emerging AI franchise, while risks revolve around reimbursement pressures, unproven AI economics, and a premium valuation without trailing profits. Analyst dispersion between the low-$80s and mid-$90s underscores differing views on execution speed and credibility. Reaching $90 will likely hinge on sustained margin progress, additional target revisions, and how the market values the AI narrative over the coming quarters.
Using Tickeron Tools in Practice
When evaluating names like this one, I often turn to Tickeron’s suite of AI-driven platforms to cross-check patterns and generate additional ideas. The AI Daily Buy/Sell Signals tool, for instance, provides an automated layer that complements traditional research and helps identify potential entry or exit points based on real-time conditions. It has become a regular part of my workflow for staying objective amid shifting fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
RDNT in upward trend: 10-day moving average broke above 50-day moving average on November 04, 2026
The 10-day moving average for RDNT crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 10 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on RDNT as a result. In 64 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for RDNT just turned positive on October 22, 2026. Looking at past instances where RDNT's MACD turned positive, the stock continued to rise in 47 of 55 cases over the following month. The odds of a continued upward trend are 85%.
RDNT moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where RDNT advanced for three days, in 230 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Aroon Indicator entered an Uptrend today. In 181 of 210 cases where RDNT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.
Bearish Trend Analysis
The 10-day RSI Indicator for RDNT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 29 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RDNT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
RDNT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.457) is normal, around the industry mean (67.298). RDNT's P/E Ratio (-292.308) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.260) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.567) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 36 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. RDNT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical imaging services
Industry MedicalSpecialties
Advertisement